1. Generics Bulletin
  2. >>Business

Neuraxpharm Targets Austria With Easypharm Deal

CNS Specialist Underlines OTC Ambitions With Easypharm Acquisition

 
• By Tom Gallen and Dave Wallace

Neuraxpharm has opened a unit in Austria after snapping up local consumer healthcare specialist Easypharm.

Map_Pin_Austria
Neuraxpharm has opened a unit in Austria after acquiring Easypharm • Source: Shutterstock

Neuraxpharm is taking its first steps into Austria and continuing its push into Europe’s branded OTC market by opening a dedicated Austrian subsidiary after acquiring consumer healthcare specialist Easypharm for an undisclosed sum.

The new Austrian unit will become part of the company’s Central European region that currently includes Germany and Poland

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.